CombiMatrix Molecular Diagnostics has added three people to its management team, the company's parent, Acacia Research, said this week.
Matthew Moore has become director of research and development. He joins CMD from US Labs, where he was part of the research and development team. Moore holds a PhD from the University of New South Wales in Australia.
Robert Embree has become director of laboratory operations. Previously, he was managing director of global immunohistochemistry and virtual image analysis of US Labs. He holds a BS from the University of Redlands in Southern California.
John Besser has joined CMD as chief financial officer. He comes to CMD from the Quest Diagnostics Nichols Institute, where he served as controller. Besser holds a BS in business management from the University of Utah.
Douglas Liu has joined Qiagen as vice president of global operations, the company said this week. He will also serve on the firm's executive committee and will be based at Qiagen's headquarters in Hilden, Germany. Liu comes to Qiagen from Bayer Healthcare, where he was head of operations for nucleic acid diagnostics in the US and worked in strategic planning and consulting at Bayer's headquarters in Germany. Liu holds an MBA from Boston University and a BS from the University of Illinois.
Trevor Hawkins has joined the board of directors of Tm Bioscience, replacing Geoffrey Beattie, the company said this week. He is the chief science and technology officer of MDS. Prior to that, he was president of the molecular diagnostics business unit of GE Healthcare. Previously, he was senior vice president of development and new business initiatives and senior vice president of genomics at Amersham Biosciences. Hawkins holds a bachelor of science from the University of Sussex and a PhD in biochemistry from the University of Sussex and MCR Laboratory of Molecular Biology in Cambridge, UK.
Tim Tasker has been appointed as executive vice president of clinical development and a member of the executive committee of Evotec, the Hamburg, Germany-based drug-discovery firm said last week. Tasker most recently served as vice president of global clinical units, clinical pharmacology, and discovery medicine at GlaxoSmithKline. He holds an MD from London University and a BA in physiological sciences from the University of Oxford.
Nassim Usman has been named entrepreneur-in-residence, focusing on investment opportunities in biotechnology, at Morgenthaler Ventures. Previously, he was senior vice president and COO of Sirna Therapeutics. Prior to that, he was CSO at Sirna, as well as its previous incarnation, Ribozyme Pharmaceuticals. He has also served on the board of directors at Archemix and Atugen. Usman holds a BSc and PhD in chemistry from McGill University.
Precision System Science last week announced that it has developed its Magtration System 12XP for sample preparation in DNA microarray experiments. The system is based on PSS's proprietary technology for nucleic acid extraction using magnetic particles and automates preprocessing procedures required for DNA, the company said.
PSS also said that Amersham Biosciences, a Japanese subsidiary of GE Healthcare, will collaborate in sales of the system and will supply PSS with its proprietary reagents for cDNA and cRNA synthesis. The combined system will be available in Spring 2006.